NCT00232310 - Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Atrial FibrillationAtrial Flutter

Interventions

DRUG

CELIVARONE (SSR149744C)

Trial Locations (9)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Porto Salvo